We were delighted to meet with Messoud Ashina (University of Copenhagen, Copenhagen, Denmark) to discuss the long term safety and tolerability profile of atogepant, and its place as a preventative option for migraine.
The abstract entitled: ‘Long-term Safety and Tolerability of Atogepant 60 mg Following Once Daily Dosing Over 1 Year for the Preventive Treatment of Migraine’ was presented at the American Academy of Neurology Virtual Annual Meeting 2021.
1. What has the study taught us about the long term safety and tolerability profile of atogepant? (0:14)
2. What place is atogepant likely to play in the preventative treatment paradigm for migraine? (3:01)
Disclosures: Messoud Ashina has received personal fees from AbbVie/Allergan, Amgen, Eli Lilly, Lundbeck, Novartis and Teva; is the principal investigator for AbbVie/Allergan, Amgen, Eli Lilly and Lundbeck in ongoing clinical trials; has received Research grants form Lundbeck Foundation, Novo Nordisk Foundation, and Novartis; has no ownership interest and does not own stocks of any pharmaceutical company. Messoud Ashina is also an Associate Editor of Cephalalgia and associate editor of the Journal of Headache and Pain, and is the President of the International Headache Society.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Victoria Jones.
Filmed as a highlight of AAN Annual Virtual Meeting 2021.
Share this Video
Related Videos In Headache Disorders
Raquel Gil-Gouveia, EAN 2022: Highlights in headache and migraine – Treatment advances, strategies for prevention, Anti-CGRP use in migraine, COVID-19
Headache is one of the most common nervous system disorders. In an interview with touchNEUROLOGY, Dr Raquel Gil-Gouveia (Hospital da Luz, Lisbon, Portugal) summarizes the ePoster session she chaired at EAN 2022, ranging from topics such as how COVID-19 has impacted on young people with headaches, the potential of new treatments such as eptinezumab and […]
Stewart Tepper, AAN 2022: Limitations of current treatments for acute migraine
The limitations of the current treatment of acute migraine are said to be patient variability and migraine attack variability. Prof. Stewart Tepper (Dartmouth-Hitchcock Medical Centre, Lebanon, NH, USA) discusses the limitations of current treatments for acute migraine and how new treatments overcome these. The abstract entitled ‘Efficacy and Safety of AXS-07 (MoSEIC Meloxicam-Rizatriptan) for the […]
Stewart Tepper, AAN 2022: Phase III MOMENTUM trial results, investigating meloxicam-rizatriptan for the acute treatment of migraine
Meloxicam-Rizatriptan (AXS-07) is a novel, oral, rapidly absorbed, multi-mechanistic, investigational medicine which combines meloxicam and rizatriptan for the acute treatment of migraine. Prof. Stewart Tepper (Dartmouth-Hitchcock Medical Centre, Lebanon, NH, USA) joins us to discuss the phase III MOMENTUM trial aims and design, and the efficacy, safety and tolerability findings of Meloxicam-Rizatriptan for the acute […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!